What do data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?

The MDS Hub was pleased to speak to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE, during the Society of Hematologic Oncology (SOHO) 2023 Annual Meeting. We asked, “What do data from the phase III COMMANDS trial reveal about luspatercept as a treatment option?”

Platzbecker discusses the open-label, randomized, controlled, phase III COMMANDS trial (NCT03682536), previously covered by the MDS Hub, which investigated luspatercept versus epoetin alfa for the treatment of anemia in transfusion-dependent, erythropoiesis-stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS). He highlights the association of treatment with luspatercept and improved transfusion independence found in the trial, and discusses the impact of these results on clinical practice.